Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 261

The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.

Mass Treatment with Single-Dose Azithromycin for Trachoma

Open access
Solomon, Anthony W., Holland, Martin J., Alexander, Neal D.E., Massae, Patrick A., Aguirre, Aura, Natividad-Sancho, Angels, Molina, Sandra, Safari, Salesia, Shao, John F., Courtright, Paul, Peeling, Rosanna W., West, Sheila K., Bailey, Robin L., Foster, Allen, Mabey, David C.W.·2004·New England Journal of Medicine

Abstract

BACKGROUND: Trachoma, caused by repeated ocular infection with Chlamydia trachomatis, is an important cause of blindness. Current recommended dosing intervals for mass azithromycin treatment for trachoma are based on a mathematical model. METHODS: We collected conjunctival swabs for quantitative polymerase-chain-reaction assay of C. trachomatis before and 2, 6, 12, 18, and 24 months after mass treatment with azithromycin in a Tanzanian community in which trachoma was endemic. For ethical reasons, at 6, 12, and 18 months, we gave tetracycline eye ointment to residents who had clinically active trachoma. RESULTS: At baseline, 956 of 978 residents (97.8 percent) received either one oral dose of azithromycin or (if azithromycin was contraindicated) a course of tetracycline eye ointment. The prevalence of infection fell from 9.5 percent before mass treatment to 2.1 percent at 2 months and 0.1 percent at 24 months. The quantitative burden of ocular C. trachomatis infection in the community was 13.9 percent of the pretreatment level at 2 months and 0.8 percent at 24 months. At each time point after baseline, over 90 percent of the total community burden of C. trachomatis infection was found among subjects who had been positive the previous time they were tested. CONCLUSIONS: The prevalence and intensity of infection fell dramatically and remained low for two years after treatment. One round of very-high-coverage mass treatment with azithromycin, perhaps aided by subsequent periodic use of tetracycline eye ointment for persons with active disease, can interrupt the transmission of ocular C. trachomatis infection.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa040979

Cites

19 of 19 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 19 references

Cited by

See all 261

Metadata

Authors
Solomon, A. W., Holland, M. J., Alexander, N. D. E., Massae, P. A., Aguirre, A., Natividad-Sancho, A., Molina, S., Safari, S., Shao, J. F., Courtright, P., Peeling, R. W., West, S. K., Bailey, R. L., Foster, A., & Mabey, D. C. W.
Venue
New England Journal of Medicine
Published
2004-11-04
Volume
351
Issue
19
Pages
1962-1971
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2138904885
Cited by
261
References
19
FWCI
21.05
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mass Treatment with Single-Dose Azithromycin for Trachoma. https://app.cochat.ai/papers/10.1056/nejmoa040979
The paper
Solomon, A. W., Holland, M. J., Alexander, N. D. E., Massae, P. A., Aguirre, A., Natividad-Sancho, A., Molina, S., Safari, S., Shao, J. F., Courtright, P., Peeling, R. W., West, S. K., Bailey, R. L., Foster, A., & Mabey, D. C. W. (2004). Mass Treatment with Single-Dose Azithromycin for Trachoma. New England Journal of Medicine. https://doi.org/10.1056/nejmoa040979

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.